These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 27134246

  • 1. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C, Medina-Rosas J, Santos AM, Jaimes DA, Arbeláez AM, Romero C, Cortes A, Londono J.
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [Abstract] [Full Text] [Related]

  • 2. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 3. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
    Liu CC, Manzi S, Kao AH, Navratil JS, Ruffing MJ, Ahearn JM.
    Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
    [Abstract] [Full Text] [Related]

  • 4. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A, Magder LS, Barr SG, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [Abstract] [Full Text] [Related]

  • 5. A surge in anti-dsDNA titer predicts a severe lupus flare within six months.
    Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.
    Lupus; 2014 Mar; 23(3):293-8. PubMed ID: 24316605
    [Abstract] [Full Text] [Related]

  • 6. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W.
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [Abstract] [Full Text] [Related]

  • 7. Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity.
    Emad Y, Gheita T, Darweesh H, Klooster P, Gamal R, Fathi H, El-Shaarawy N, Gamil M, Hawass M, El-Refai RM, Al-Hanafi H, Abd-Ellatif S, Ismail A, Rasker J.
    Reumatismo; 2018 Jul 06; 70(2):85-91. PubMed ID: 29976042
    [Abstract] [Full Text] [Related]

  • 8. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
    Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, Danchenko N, Ahearn JM, Manzi S.
    Arthritis Rheum; 2010 Mar 06; 62(3):837-44. PubMed ID: 20187154
    [Abstract] [Full Text] [Related]

  • 9. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 10. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 15; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 11. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar 15; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 12. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups.
    Ann Rheum Dis; 2012 Nov 15; 71(11):1833-8. PubMed ID: 22550315
    [Abstract] [Full Text] [Related]

  • 13. Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica: a comparative analysis.
    Maloney KC, Ferguson TS, Stewart HD, Myers AA, De Ceulaer K.
    Lupus; 2017 Nov 15; 26(13):1448-1456. PubMed ID: 28480787
    [Abstract] [Full Text] [Related]

  • 14. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies.
    Gheita TA, Abaza NM, Hammam N, Mohamed AAA, El-Gazzar II, Eissa AH.
    Lupus; 2018 Jun 15; 27(7):1081-1087. PubMed ID: 29460701
    [Abstract] [Full Text] [Related]

  • 15. Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody.
    Saigal R, Goyal LK, Agrawal A, Mehta A, Mittal P, Yadav RN, Meena PD, Wadhvani D.
    J Assoc Physicians India; 2013 Jun 15; 61(6):372-7. PubMed ID: 24640201
    [Abstract] [Full Text] [Related]

  • 16. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1143-51. PubMed ID: 19714615
    [Abstract] [Full Text] [Related]

  • 17. International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies.
    Bentow C, Lakos G, Martis P, Wahl E, Garcia M, Viñas O, Espinosa G, Cervera R, Sjöwall C, Carmona-Fernandes D, Santos MJ, Hanly JG, Mahler M.
    Lupus; 2016 Jul 15; 25(8):864-72. PubMed ID: 27252263
    [Abstract] [Full Text] [Related]

  • 18. Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus.
    Zivković V, Stanković A, Cvetković T, Mitić B, Kostić S, Nedović J, Stamenković B.
    Srp Arh Celok Lek; 2014 Jul 15; 142(7-8):431-6. PubMed ID: 25233687
    [Abstract] [Full Text] [Related]

  • 19. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A, Chakravarty E, James JA, Merrill JT.
    Rheumatology (Oxford); 2014 Dec 15; 53(12):2175-81. PubMed ID: 24729400
    [Abstract] [Full Text] [Related]

  • 20. Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus.
    Suleiman S, Kamaliah D, Nadeem A, Naing NN, Che Maraina CH.
    Int J Rheum Dis; 2009 Jul 15; 12(2):100-6. PubMed ID: 20374326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.